Abstract Radiotherapy is a treatment choice for local control of breast cancer, particularly after the removal of tumor tissues by surgery. However, intrinsic radioresistance of cancer cells limits therapeutic efficacy. Here, we determined in breast cancer cells the potential radiosensitizing activity of SM-164, a small molecule compound, that mimics the activity of SMAC, a mitochondrial protein released during apoptosis to activate caspases by inhibiting cellular inhibitor of apoptosis proteins, cIAP-1, and XIAP. We found that SM-164 at nanomolar concentrations promoted degradation of cIAP-1, disrupted the inhibitory binding of XIAP to active caspase-9, and sensitized breast cancer cells to radiation with a sensitization enhancement ratio (SER) of 1.7-1.8. In one line of breast cancer cells resistant to SM-164 as a single agent, SM-164 radiosensitization was mediated by intrinsic apoptosis pathway through activation of caspases-9 and -3. In a line of breast cancer cells sensitive to SM-164 as a single agent, SM-164 radiosensitization was mediated by both extrinsic and intrinsic apoptosis pathways through activation of caspases-9, -8, and -3. Consistently, blockage of caspase activation, through siRNA knockdown or treatment with a pan-caspase inhibitor z-VAD-fmk, inhibited apoptosis and abrogated SM-164 radiosensitization. Our study demonstrates that IAPs are valid radiosensitizing targets in breast cancer cells and SM-164 could be further developed as a novel class of radiosensitizers for the treatment of radioresistant breast cancer.
Introduction
Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among women, which accounts for 23% of the total cancer cases and 14% of the cancer deaths [1] . Although early detection contributes to the decrease of the mortality rates, the high incidence of breast cancer requires continued use of different treatment modalities, including combinations of surgery, radiotherapy, and chemotherapy. Radiotherapy plays a crucial role in achieving the local control of the disease, particularly after conservative surgery [2] . However, development of radioresistance in breast cancer cells limits the curable potential and contributes to local recurrences [3] . Thus, development of therapeutic agents that sensitize breast cancer to radiation will be extremely important for the improvement of therapeutic outcome.
Increasing lines of evidence suggest that radioresistance of breast cancer is associated with overexpression of epidermal growth factor receptors (e.g. HERS), insulin-like growth factor-1 receptor (IGF-1R), endothelial growth factor (VEGF), activation of PI3K pathway, and defects in DNA damage response pathways. Furthermore, the status of p53, BRCA, and BCL2 family members also determines radiation responsiveness (for reviews, see [3] [4] [5] [6] ). However, it remains elusive if inhibitor of apoptosis proteins (IAPs), a well-known family of anti-apoptotic proteins, plays a role in conferring breast cancer cells to radioresistance and if targeting IAPs would induce radiosensitization.
IAP family proteins consist of at least seven members, including XIAP, cIAP-1, cIAP-2, NAIP, Survivin, Livin/ ML-IAP, and Bruce, which are characterized by containing one or several BIR (baculoviral IAP repeat) domains required for suppression of apoptosis. Some family members also have a RING finger domain at the C-terminus that is required for their E3 ubiquitin ligase activity [7] . The main function of IAPs is to suppress apoptosis through binding to and thus inhibiting active caspases 3/7 and 9. The most potent inhibitor of caspases among IAP family members is XIAP with sub-nanomole inhibitory constants. In XIAP, the third BIR domain (BIR3) potently inhibits the activity of the active caspase 9, whereas the linker region between BIR1 and BIR2, together with the BIR2 domain, selectively targets the active caspases 3 and 7 [8] .
Second mitochondria-derived activator of caspase (SMAC) is a mitochondrial protein that is released to the cytoplasm on induction of apoptosis [9, 10] . In its dimeric form, SMAC through its AVPI tetrapeptide binding motif interacts with both BIR2 and BIR3 domains of multiple IAPs to release the binding of IAPs to both initiator (caspase 9) and effector (caspase 3/7) caspases [11, 12] . SMAC or a synthetic SMAC peptide with AVPI in its N-terminus is sufficient to activate caspase-3 [11, 13] and sensitizes cancer cells to apoptosis induced by chemotherapeutic agents [14] and radiation [15] . Indeed, several SMAC mimetic small molecules have been discovered, which acting as a new class of anticancer drugs, effectively overcome apoptosis resistance in different types of cancer cells with high levels of IAPs and sensitize cancer cells to current chemotherapeutic agents in vitro and in vivo [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . Although overexpression of SMAC protein itself enhanced radiation-induced apoptosis in several lines of cancer cells, including neuroblastoma, glioblastoma, and pancreatic carcinoma [15] , it remains elusive whether SMAC mimetics can act as a radiosensitizing agent.
SM-164 is a water-soluble and cell-permeable bivalent SMAC mimetic compound that binds to both the BIR2 and BIR3 domains of XIAP with a Ki of 0.56 nM. SM-164 also binds to cIAP-1 and cIAP-2 proteins with Ki of 0.31 and 1.1 nM, respectively [17, 26, 28] . We have recently shown that SM-164 acts as a novel class of radiosensitizers that confers a subset of otherwise radioresistant head and neck squamous carcinoma cells (HNSCC) to radiation [27] . In this study, we investigated if SM-164 acts as a radiosensitizer in breast cancer cells, which has not been previously investigated. Our data showed that SM-164 acts as a potent radiosensitizing agent with mechanism involving caspase activation and apoptosis induction.
Materials and methods

Compound
SM-164, a water-soluble and cell-permeable SMAC mimetic compound, binds to both the BIR2 and BIR3 domains of XIAP with a Ki of 0.56 nM. SM-164 also binds to cIAP-1 and cIAP-2 proteins with Ki of 0.31 and 1.1 nM, respectively [17, 26, 28] . The synthesis of this compound was performed as described previously [17, 26] .
Cell culture
Breast cancer lines, including SK-BR-3, MDA-MB-468, MDA-MB-453, MCF-7, ZR-75-1, T-47D, along with immortalized breast epithelial MCF10A, were obtained from ATCC and were grown in DMEM (Gibco) with 10% fetal bovine serum. MCF 10A cells were cultured in Cell Culture Basal Media for mammary epithelial cells (MEBM, Biowhittaker Technologies, Inc).
Radiation exposure and clonogenic assay Cells were seeded in 60-mm dishes at proper cell densities in duplicate and exposed to different doses of radiation (Philips RT250, Kimtron Medical) after 24-h pretreatment with SM-164, followed by incubation at 37°C for 6-11 days. Survival curves were fitted using the linearquadratic equation, and the mean inactivation dose was calculated [29] . Irradiations were performed in the Experimental Irradiation Core of the University of Michigan Cancer Center.
Western blot analysis
The assay was performed as described [24] . The sources of antibodies used are as follows: cIAP-1 (a gift from Dr. Silke at La Trobe University, Australia) [30] , XIAP (BD Pharmingen, CA), cIAP-2, PARP and Caspase-3 (Cell Signaling, MA), Caspase-9 (Santa Cruz Biotechnology, CA), Caspase-8 (Calbiochem, NJ), and b-Actin (Sigma, MO). Beadsconjugated mouse anti-HA (Sigma, MO), Rabbit anti-HA (Sigma, MO), and Rat anti-HA (Roche, CA).
ATPlite growth assay and IC50 determination Cell were seeded in 96-well plates in triplicate and treated the next day with SM-164 in various doses ranging from 0.03 to 10 lM for 24 h. The viability of the cells was then measured using one-step ATPlite cell proliferation assay (Perkin Elmer) [24] .
DNA fragmentation assay
Cells were seeded in 100-mm dishes at 2.0 9 10 6 (MDA-MB-468) or 0.5 9 10 6 (SK-BR-3) cells per dish, and pretreated next day with DMSO (control) or SM-164 (200 nM) for 6 h before being exposed to radiation (6 Gy). The cells were harvested for 24 h (MDA-MB-468) or 48 h (SK-BR-3) post-radiation by scraping, pelleted and lysed in 600 ll of lysis buffer (5 mM Tris-HCl, pH 8, 20 mM EDTA, and 0.5% Triton X-100). The fragmented DNAs in the supernatant after 14,000 rpm centrifugation were extracted with PCI (phenol/chloroform/isopropanol) (Fisher) and precipitated with ethanol, followed by electrophoresis in a 1.8% agarose gel [24] .
siRNA silencing of caspases-3, -8, and -9
The siRNA oligonucleotides for silencing caspase-3 (
, and scrambled control siRNA (siCONT: 5 0 -ATTGTATGCGATCGCAGACTT-3 0 ) were from Dharmacon (USA). Cells were transfected with siR-NA using Lipofectamine 2000 and split 48 h late. One portion was used for clonogenic assay or DNA fragmentation and the other portion for Western blotting [31] .
FACS (fluorescence-activated cell sorting) analysis
Cells were treated with SM-164 or exposed to radiation alone or in combination. Cells were harvested at 24 or 48 h post-radiation and analyzed by a flow cytometry [24] .
Caspase activation assay
The activity of caspase-3, -9, or -8 was analyzed using a fluorogenic caspase assay with Z-DEVD-AFC, Ac-LEHD-AFC (Calbiochem), or Ac-IETD-AFC (BD Pharmingen) as a substrate, respectively [27] . The results are expressed as fold changes compared with the control.
Immunoprecipitation SK-BR3 cells were transiently transfected with pEBB-HA-XIAP. About 48 h later, cells were pretreated with SM164 for 2 h, followed by radiation. Cells were lysed 24 h postradiation in a lysis buffer containing freshly added protease inhibitor tablet [24] . XIAP was pulled down using beadsconjugated anti-HA antibody, and bound active caspase-9 was detected by Western blotting using anti-caspase-9 antibody.
Statistical analysis ANOVA were used with SPSS (Statistical Product and Service Solution) software for statistical comparisons involving multiple groups, followed by SNK post hoc test to determine significance of each two group (P \ 0.05). Paired or unpaired two-tailed Student t test was performed in comparison between two groups, using SAS software.
Results
Expression of family members of IAPs among breast cancer cell lines
To determine if IAPs are potential radiosensitizing targets for breast cancer cells, we measured the levels of three most common family members, cIAP-1, cIAP-2, and XIAP, in six breast cancer cell lines by Western blotting. As shown in Fig. 1a , the levels of cIAP-1 varied among different lines with a high expression in four lines and low expression in other two. While cIAP-2 expression was only detectable in MDA-MB-468 cells, XIAP expression varies with three lines expressing relatively higher levels than other three. Among all six lines tested, MDA-MB468 was the only line having a high expression of all three family members, whereas SK-BR3 line had a high expression of both cIAP-1 and XIAP.
SM-164 was shown to be a potent inducer of cIAP-1 degradation in HNSCC cells [27] . We next determined the sensitivity of four breast cancer lines (MDA-MB-468, MDA-MB-453, T47D, and SK-BR-3) with high expression of cIAP-1 to SM-164-mediated degradation. As shown in Fig. 1b , treatment of cells with SM-164 at 10 (in case of T-47D and SK-BR-3) or 100 nM (in case of MDA-MB-468 and MDA-MB-453) for 1 h caused complete elimination of cIAP1, whereas SM-173, a structural inactive analogue [26] , was completely inactive at 100 nM. SM-164 had no effects on XIAP levels (Fig 1c and data not shown) . We also included MCF10A, an immortalized breast epithelial cells [32] as a normal control, and found that cIAP-1 was not expressed in this line. The results indicate that SM-164 induces rapid degradation of cIAP-1 at low nanomolar concentrations in breast cancer cells.
Sensitivity of breast cancer cells to SM-164 as a single agent or in combination with radiation
We next determined the sensitivity of these four breast cancer lines, along with MCF10A cells, to SM-164 at various drug concentrations up to 10 lM for 24 h treatment, using an ATP-lite cell proliferation assay. As shown in Fig. 2a , three lines (SK-BR3, MDA-MB-453, and T47D), along with MCF10A cells, are resistant to SM-164 as a single agent with only 10-15% growth inhibition at 10 lM SM-164. In contrast, MDA-MB-468 cells are relatively sensitive to SM-164 with 60% growth inhibition after exposure to 10 lM SM-164 for 24 h. Thus, most breast cancer cell lines, along with one immortalized line, are resistant to SM-164 as a single agent. Furthermore, it appears that cellular sensitivity to SM-164 as a single agent is not determined by the levels of cIAP-1, given the fact cIAP-1 was degraded by SM-164 in all tested breast cancer cells regardless of their drug sensitivity.
We then chose one resistant line (SK-BR3) and one sensitive line (MDA-MB-468) to determine potential radiosensitization activity of SM-164, given the fact that both lines had (1) high levels of cIAP-1 and XIAP, and (2) formed countable colonies in standard clonogenic assay. MCF10A line was not included because of its inability to form the colonies from single cell. Cells were treated with SM-164 alone at 200 nM, which is sufficient to degrade cIAP-1, or in combination with different doses of radiation. As shown in Fig. 2b and c, SM-164 induced a remarkable radiosensitzation with a SER (sensitization enhancement ratio) of 1.7 and 1.8 in both SM-164-resistant SK-BR3 and SM-164-sensitive MDA-MB-468 cells, respectively.
Radiosensitization by SM-164 is associated with enhanced apoptosis
To determine the nature of SM-164 radiosensitization, we treated SK-BR-3 and MDA-MB-468 cells with SM-164 (200 nM) and radiation (6 Gy), alone and in combination, for 24 and 48 h, followed by FACS analysis to detect sub-G1 apoptotic population. In SM-164-resistant SK-BR-3 cells, SM-164 treatment had little effect on apoptotic sub-G1 population, whereas radiation exposure alone or in combination with SM-164 caused a moderate increase in apoptotic cells at 24 h, but a substantially increase at 48 h. The difference between groups of combinational and radiation alone treatment was statistically significant (P \ 0.05) (Fig. 3a, left panel) . In contrast, in sensitive MDA-MB-468 cells, single agent treatment with SM-164, but not with radiation for 24 h, caused a significant induction of apoptosis (P \ 0.01), which was further enhanced when SM-164 was combined with radiation (P \ 0.01). At 48 h, combinational treatment had a synergetic effect on apoptosis induction (P \ 0.01) (Fig. 3a , right panel).
To further confirm that SM-164 radiosensitization was associated with apoptosis induction, we measured three well-established biochemical markers of apoptosis. First, the assay for DNA fragmentation, the hall-marker of apoptosis, revealed that in SM-164-resistant SK-BR3 cells, the 180-bp DNA ladders were only obviously seen in SM-164/radiation combinational treatment group, whereas in SM-164-sensitive MDA-MB-468 cells, single treatment with SM-164, but not with radiation, caused the substantial DNA fragmentation, which was further enhanced by radiation (Fig. 3b) . Consistently, other two biochemical assays of apoptosis, PARP cleavage and caspase-3 activation/ cleavage, also demonstrated a maximal induction of cleaved PARP and caspase-3 by combinational treatment in both lines (Fig. 3c) . These results strongly suggested that SM-164 radiosensitization is associated with enhanced apoptosis with potential involvement of caspase activation.
SM-164 radiosensitization is associated with caspase activation in breast cancer cells
Because the mechanism of SM-164 action is to promote cIAP-1 degradation and to disrupt XIAP binding to active caspases [26] , and we have observed caspase-3 activation on combinational treatment (Fig. 3c) , we reasoned that SM-164 radiosensitization would be associated with caspase activation in breast cancer cells. We, therefore, determined a direct involvement of caspase activation in SM-164 radiosensitization. Cells were treated with SM-164, radiation alone or in combination and activity of caspase-3, -8, and -9 was measured. As shown in Fig. 4a-c, in resistant SK-BR-3 cells, single treatment with SM-164 or radiation caused a minor, if any, activation of caspase-9 and -3, whereas combinational treatment significantly activated both caspase-9 and -3 up to 3-fold (P \ 0.01). Neither single nor combinational treatment has any measurable effect on caspase-8 activation. In contract, in sensitive MDA-MB-468 cells, single treatment with SM-164, but not with radiation, caused a 2-, 2.3-, and 4.4-fold activation of caspases-8, -9, and -3, respectively. Significantly, combinational treatment caused a significant increase of active caspases with an up to 4-, 5-, and 8-fold activation of caspases-8, -9, and -3, respectively (P \ 0.05 or P \ 0.01). Taken together, these results suggest that SM-164 radiosensitization in SK-BR-3 cells is mediated by intrinsic mitochondrial apoptosis pathway, whereas in MDA-MB-468 cells, it is mediated by both extrinsic death receptor and intrinsic mitochondrial apoptosis pathways.
SM-164 abrogates the binding between XIAP and active caspase-9
Because mitochondrial apoptosis pathway is involved in SM-164 radiosensitization, we reasoned that this pathway is likely activated through SM-164 disruption of XIAPcaspase-9 binding, as previously shown in a cell-free biochemical assay [26] . To test this hypothesis, we transiently transfected HA-tagged XIAP into SK-BR-3 cells, followed by treatment with SM-164 or radiation, alone, or in Cells were treated with SM-164 or radiation (6 Gy) alone or in combination (SM-164 pretreatment for 6 h, followed by radiation exposure). Cells were then harvested and analyzed by FACS profiling for apoptosis (sub-G1 population) at 24 or 48 h post-radiation, respectively. Shown is mean ± SEM from three independent experiments (*P \ 0.05; **P \ 0.01). combination. Ectopically expressed XIAP was then pulled down by immunoprecipitation with beads-conjugated HA antibody and XIAP-bound active caspase-9 was detected by anti-capase-9 antibody. As shown in Fig. 4d, a basal very low level of active caspase-9 was found to bind to XIAP (lane 2). The amount of XIAP-bound active caspase-9 was significantly increased on radiation exposure (lane 3), which was remarkably inhibited by SM-164 (lane 4). Fig. 4 SM-164 activates caspases alone or in combination with radiation (a-c) Cells were treated with SM-164 or radiation (6 Gy) alone or in combination (SM-164 pretreatment for 6 h, followed by radiation exposure). Cells were then harvested and analyzed by ELISA-based caspase activity assay for caspase-8 (a), -9 (b) and -3 (c) at 24 h (MDA-MB-468) or 48 h (SK-BR-3) post-radiation, respectively. Shown are mean ± SEM from three independent experiments (*P \ 0.05; **P \ 0.01). d SM-164 disrupts the binding between XIAP and active caspase-9: SK-BR-3 cells were transiently transfected with HA-XIAP, followed by SM-164 (200 nM) pretreatment for 2 h and then radiation (6 Gy). Cells were harvested 24 h postradiation. Cell lysates (*2 mg protein) were immunoprecipitated with beadsconjugated HA-antibody and bound active caspase-9 was detected by Western blotting using anti-caspase-9 antibody. Whole cell extract (WCE) was subjected to direct Western blotting using anti-HA antibody Thus, SM-164 radiosensitization in SK-BR-3 cells is mediated by releasing XIAP from its binding to active caspase-9, leading to subsequent caspase-3 activation and apoptosis induction.
Blockage of caspase activation largely abrogated SM-164 enhancement of apoptosis and radiosensitization Finally, we tested if caspase activation, which leads to apoptosis induction, is the main cause for SM-164 radiosensitization. We used two approaches to inactivate caspases by (a) z-VAD-fmk, a pan caspase inhibitor and (b) siRNA silencing/knockdown. As shown in Fig. 5a and b, z-VAD-fmk treatment completely blocked apoptotic DNA fragmentation induced by combination of SM-164 and radiation in both SK-BR3 and MDA-MB-468 cells. Consequently, z-VAD-fmk largely abrogated SM-164 radiosensitization with SER reduction from 1.72 to 1.27 in SK-BR3 cells and 1.68-1.36 in MDA-MB-468 cells, both are statistically significant (P \ 0.05) (Fig. 5c, d ).
We next used siRNA silencing/knockdown approach in SK-BR3 cells and found that caspase-3 knockdown completely inhibited apoptotic DNA fragmentation (Fig. 6a) . Consistently, siRNA knockdown of caspase-9 and caspase-3 ( Fig. 6b) significantly abrogated SM-164 radiosensitization with SER reduction from 1.57 to 1.27 or 1.23, respectively, (P \ 0.05) (Fig. 6c) , whereas caspase-8 knockdown (Fig. 6b ) had no effect with SER change from Shown are mean ± SEM from two independent experiments, each runs in duplicate 1.57 to 1.55, as expected (Fig. 6c) . Taken together, these results indicated that SM-164 radiosensitization is causally related to activation of caspases and induction of apoptosis.
Discussion
Discovery of mechanism-based anticancer cancer drugs relies on thorough validation of potential cancer targets.
Targeting apoptosis signaling pathways have attracted much attention in past decades with few promising agents advanced to the phase I/II clinical trials [33] [34] [35] . One appealing target among the targets of apoptosis pathways is the IAPs family, which binds to both an initiator caspase (caspase-9) and effector caspases (caspase-3 and -7) to block caspase-dependent apoptosis. Thus, targeting these negative blockers of caspases triggers apoptosis and sensitizes cancer cells to conventional chemo and radiation therapies [36] . Our previous study revealed that most breast cancer cell lines are resistant to a SMAC mimetic compound [16] as a single agent, which sensitized sensitive cells much more effectively than resistant cells to cell killing induced by TRAIL or etoposide [24] . In this study, we showed that most breast cancer cell lines are also resistant to SM-164, a potent inhibitor of IAPs [26] , as a single agent, but SM-164 acts as a radiosensitizing agent equally effective in both sensitive MD-MBA-468 cells and resistant SK-BR-3 cells, suggesting that SM-164 is a potent radiosensitizer in breast cancer cells. It is well established that in vertebrate cells, apoptosis typically proceeds through one of two signaling cascades termed the intrinsic mitochondrial and extrinsic death receptor pathways, both of which converge on activating the executioner caspases, caspase-3, and caspase-7 [37, 38] . Our study revealed mechanistically that cellular sensitivity to SM-164 as a single agent is attributable to its intrinsic sensitivity to caspase-8 activation, followed by activation of extrinsic apoptosis pathway when cIAP is degraded by SM-164. On the other hand, SM-164 radiosensitization in resistant cells is mainly mediated by activation of intrinsic apoptosis pathway because of disruption of XIAP-casapse-9 binding, leading to full activation of caspase-9.
We elucidated that the underlying mechanism of SM-164 radiosensitization is mainly through activation of caspases and induction of apoptosis. This conclusion was strongly supported by the functional rescue experiments in which blockage of apoptosis through inactivation of caspases using pharmaceutical (z-VAD) or molecular biology (siRNA) approaches largely abrogates SM-164 radiosensitization. Thus, induction of apoptosis through caspase activation plays a key role in radiosensitization by SM-164 in breast cancer cells. These results are consistent with our recent finding of SM-164 radiosensitization in head and neck squamous carcinoma cells, which is dependent on intrinsic sensitivity to caspase activation and apoptosis induction [27] .
In summary, we report here that SM-164 is a potent and novel class of radiosensitizers for breast cancer cells, regardless their sensitivity to SM-164 as a single agent. SM-164 radiosensitization is mainly mediated by caspase activation through removal of negative blockers cIAP-1 (through degradation) and XIAP (through disrupting its inhibitory binding to active caspase-9), leading to induction of apoptosis. Our study suggests that breast cancer patients might benefit from SM-164-radiation combinational therapy and provides the proof-of-concept for future development of SM-164 or other SMAC mimetic compounds as a novel class of radiosensitizing drugs against breast cancer cells.
